SCHEMBL6120771

SCHEMBL6120771

CO[C@@](C)(C(=O)O)c1cccc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 3/20 0.51
HSD17B10 Q99714 2/20 0.51
PPARG P37231 7/20 0.48
PPARA Q07869 7/20 0.48
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PPARD Q03181 1/20 0.44
ACP3 P15309 1/20 0.44
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42
KIF11 P52732 1/20 0.42
HPGD P15428 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
RCE1 Q9Y256 1/20 0.38
PGR P06401 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29649169 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL29697583 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL29697568 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL2723142 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL12940368 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
Mandelic Acid SCHEMBL16689936 0.89 LMNA (0.47) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL9088372 0.85 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL9087816 0.85 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL9551660 0.85 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL7945062 0.83 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11865128-B2 Aminoglycosides and uses thereof in treating genetic disorders TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-01-09 US disclosed
US-11613551-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders ELOXX PHARMACEUTICALS LTD. (IL) 2023-03-28 US disclosed
CN-114957357-A Aminoglycoside derivatives and their use in the treatment of genetic disorders ELOXX制药有限公司 2022-08-30 CN disclosed
CN-108350014-B Aminoglycoside derivatives and their use in the treatment of genetic disorders ELOXX制药有限公司 2022-06-10 CN disclosed
US-20210300958-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2021-09-30 US disclosed
US-20210228608-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2021-07-29 US disclosed
US-10973839-B2 Aminoglycosides and uses thereof in treating genetic disorders TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2021-04-13 US disclosed
US-10899785-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders ELOXX PHARMACEUTICALS LTD. (IL) 2021-01-26 US disclosed
EP-3296311-B1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS TECHNION RES & DEV FOUNDATION (IL) 2020-09-30 EP disclosed
US-20200078386-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2020-03-12 US disclosed
US-20160074425-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2016-03-17 US disclosed
US-9175029-B2 Aminoglycosides and uses thereof in treating genetic disorders TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2015-11-03 US disclosed
US-9085587-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2015-07-21 US disclosed
US-20140357590-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2014-12-04 US disclosed
US-8895519-B2 Aminoglycosides and uses thereof in treating genetic disorders TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2014-11-25 US disclosed
EP-2640734-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS Technion Research & Development Foundation Ltd. (IL) 2013-09-25 EP disclosed
US-20130237489-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2013-09-12 US disclosed
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. 2012-10-04 US disclosed
WO-2012066546-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357590-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS AARS1, GARS1, UPF1 ALDH1A1 2646/4885KDM4E 3261/4885HSD17B10 2530/4885
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS ALDH1A1 1654/4885KDM4E 3905/4885HSD17B10 691/4885
US-20210300958-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS UPF1, AARS1, NUDT21 ALDH1A1 1473/4885KDM4E 2974/4885HSD17B10 2322/4885
US-20210228608-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS AARS1, GARS1, UPF1 ALDH1A1 2646/4885KDM4E 3261/4885HSD17B10 2530/4885
US-11865128-B2 Aminoglycosides and uses thereof in treating genetic disorders AARS1, GARS1, UPF1 ALDH1A1 2646/4885KDM4E 3261/4885HSD17B10 2530/4885
US-10973839-B2 Aminoglycosides and uses thereof in treating genetic disorders AARS1, GARS1, UPF1 ALDH1A1 2646/4885KDM4E 3261/4885HSD17B10 2530/4885
US-20130237489-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS AARS1, GARS1, UPF1 ALDH1A1 2646/4885KDM4E 3261/4885HSD17B10 2530/4885
US-20160074425-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS AARS1, GARS1, UPF1 ALDH1A1 2646/4885KDM4E 3261/4885HSD17B10 2530/4885
US-11613551-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders UPF1, AARS1, NUDT21 ALDH1A1 1473/4885KDM4E 2974/4885HSD17B10 2322/4885
US-10899785-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders UPF1, AARS1, NUDT21 ALDH1A1 1473/4885KDM4E 2974/4885HSD17B10 2322/4885
US-20200078386-A1 AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS AARS1, GARS1, UPF1 ALDH1A1 2646/4885KDM4E 3261/4885HSD17B10 2530/4885
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS ALDH1A1 1654/4885KDM4E 3905/4885HSD17B10 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.